KLF17 and cancer: Recently, accumulating evidence has shown that KLF17 is downregulation in lung cancer [23], liver cancer [24], gastric cancer [25], papillary thyroid carcinoma [26], esophageal carcinoma [27], and colorectal carcinoma [28]; KLF17 downregulation increased the invasiveness of these cancers and was correlated with poor prognosis in these patients.